Akrikhin has completed the Second Phase of its Investment Program – reorganization of production of soft forms. From now on, the Company’s production of soft forms entirely corresponds to GMP Standards. Investment under the project reached 120 million RF Rubles.
In 2010 - 2016 Akrikhin is implementing the Investment Program related to modernization and reconstruction of its industrial complex in Staray Kupavna in order to boost the volumes of production(both current and planned range of products). 960 million RF Rubles investments will be allocated between four main directions: reorganization of boiler house, reconstruction and upgrading of soft forms production, reconstruction and upgrading of solid forms production and construction of a new warehouse complex. Among other things, Akrikhin’s Investment Program is aimed at ensuring the compliance of the entire industrial complex of the Company with GMP Standards.
Akrikhin commenced restructuring of soft officinal medicines production in 2010. The SOM Upgrading Project is aimed at increasing the volume of medicines produced, ensuring additional opportunities for further growth in 5 – 6 year perspective and utmost compliance of SOM production processes with GMP Standards.
In the framework of soft forms production restructuring the Company completed construction of additional 1,100 square meters of production floors, commissioned a new production facility with “clean room area” for manufacturing of non-hormonal products (ointments and gels). The Company uses the state of the art equipment (such as homogenizer supplied by IKA WERKE GmbH (Germany) etc.).
At the modernized AKRIKHIN’s soft forms production GMP Standards implemented (the Russian equivalent of the international GMP Standard is GOST R 52249-2009). Technological upgrading of Russian pharmaceutical manufacturing facilities is an integral part of Pharma-2020 – Russian Pharmaceutical Industry Development Strategy. Moreover, starting from the 1st of January 2014, according to the Federal Law No. 61 “On circulation of medicines”, the manufacturing facilities of all Russian pharmaceutical companies must correspond to GMP Standards.
Jan Slob, Akrikhin’s President: “As of today, we have completed two phases of our Investment Program: we commissioned and started up new boiler house complex and reorganized the production of non-hormonal soft forms. Reconstruction of soft forms production lines will be implemented within the period of 2010-2016. New Akrikhin’s warehouse complex will be constructed in 2012-2013. From 2010 through October 2012 Akrikhin invested 412 million in realization of its Investment Program”.